1597531-24-2

Basic information

• Product Name: (S)-(2-(3-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
• Synonyms: (S)-(2-(3-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
• CAS NO: 1597531-24-2
• Molecular Weight: 558.756
• Mol File: 1597531-24-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-(2-(3-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(2-(3-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone(1597531-24-2)
• EPA Substance Registry System: (S)-(2-(3-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone(1597531-24-2)

Safety Data

• Hazardous Substances Data: 1597531-24-2(Hazardous Substances Data)

Upstream product

• 956317-36-5 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoic acid 
• 1597531-22-0 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-hydroxybenzamidine 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 42247-74-5 2-(2-hydroxyethyl)benzonitrile 
• 1597531-51-5 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)benzonitrile 

Downstream Products

• 1597518-36-9 ((S)-2-{3-[2-(2-hydroxyethyl)phenyl]-[1,2,4]oxadiazol-5-yl}pyrrolidin-1-yl)-(5-methyl-2-[1,2,3]triazol-2-ylphenyl)methanone 

Relevant articles and documents

OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES

The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.